US Patent Issued to Nanjing GenScript Biotech on June 2 for "Anti-PD-L1/anti-LAG-3 multiple antigen binding proteins and methods of use thereof" (Chinese, Singaporean Inventors)

ALEXANDRIA, Va., June 2 -- United States Patent no. 12,643,948, issued on June 2, was assigned to Nanjing GenScript Biotech Co. Ltd. (Nanjing, China).

"Anti-PD-L1/anti-LAG-3 multiple antigen binding proteins and methods of use thereof" was invented by Zhongdao Li (Nanjing, China), Liusong Yin (Nanjing, China), Tielin Zhou (Singapore) and Zhuo Fang (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present application provides multiple antigen binding proteins containing a first antigen binding portion that specifically binds an epitope on PD-L1, preferably human PD-L1, and a second antigen binding portion that specifically binds an epitope on LAG-3. Also provided are nucleic acids encoding th...